Agenus Inc (AGEN) : Venbio Select Advisor scooped up 201,731 additional shares in Agenus Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,400,868 shares of Agenus Inc which is valued at $14,933,399.Agenus Inc makes up approximately 5.30% of Venbio Select Advisor’s portfolio.
Other Hedge Funds, Including , A.r.t. Advisors sold out all of its stake in AGEN during the most recent quarter. The investment firm sold 251,352 shares of AGEN which is valued $1,563,409. Allianz Asset Management Ag added AGEN to its portfolio by purchasing 123,875 company shares during the most recent quarter which is valued at $770,503.Artal Group S.a. boosted its stake in AGEN in the latest quarter, The investment management firm added 250,000 additional shares and now holds a total of 1,000,000 shares of Agenus Inc which is valued at $6,220,000. Agenus Inc makes up approx 0.13% of Artal Group S.a.’s portfolio.Blair William Coil boosted its stake in AGEN in the latest quarter, The investment management firm added 18,775 additional shares and now holds a total of 59,700 shares of Agenus Inc which is valued at $354,618.
Agenus Inc (AGEN) witnessed a volatile trading activity on Thursday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.2 and reached the intraday high at $6.27. The bulls started the profit booking and pushed the shares to intraday low of $6.04. The trading session was marked by a volume range of 9,25,191 shares exchanging hands. The 52-week high of the shares is $7.33 and the 52-week low is $2.61. The market cap of the company stands at $539 M and there are 8,69,99,302 shares in public circulation.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform including Retrocyte Display technology which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines and its saponin-based vaccine adjuvants QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages including a series of CPMs in investigational new drug (IND)-enabling studies Prophage Series vaccine a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM) which is a form of brain cancer and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner GlaxoSmithKline (GSK).